Comparison of naltrexone, 6α-naltrexol, and 6β-naltrexol in morphine-dependent and in nondependent rhesus monkeys

Psychopharmacology

Volumn 195, Issue 4, 2008, Pages 479-486

  Li, Jun Xu ^a   McMahon, Lance R ^a   France, Charles P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antagonism; Dependence; Drug discrimination; Monkey; Naltrexol; Naltrexone; Opioid; Schild analysis

Indexed keywords

DRUG METABOLITE; MORPHINE; NALTREXOL; NALTREXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; 6 BETA HYDROXYNALTREXONE; 6 BETA-HYDROXYNALTREXONE; DRUG DERIVATIVE; MU OPIATE RECEPTOR; NARCOTIC ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISCRIMINATION; DRUG EFFECT; DRUG POTENCY; FEMALE; MALE; MONKEY; MORPHINE ADDICTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; APPETITE; COMPARATIVE STUDY; DISCRIMINATION LEARNING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; INVERSE AGONISM; MACACA; PSYCHOLOGICAL ASPECT;

ANIMALS; APPETITIVE BEHAVIOR; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; FEMALE; MACACA MULATTA; MALE; MORPHINE; MORPHINE DEPENDENCE; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU;

EID: 36349010310     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0914-9     Document Type: Article

References (29)

1. Anton RF (2001) Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 62(Suppl 20):11-17
2. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-58
3. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E (1997) Human herpes virus KSHV encodes a constitutively active G-protein coupled receptor linked to cell proliferation. Nature (Lond) 385:347-350
4. Berg KA, Harvey JA, Spampinato U, Clarke WP (2005) Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol Sci 26:625-630
5. 1 receptor subtypes delineate residues underlying activation properties. J Biol Chem 271:28071-28076
6. Costa T, Ogino Y, Munson PJ, Onaran O, Rodbard D (1992) Drug efficacy at guaninenucleotide-binding regulatory protein linked receptors: thermodynamic interpretations of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41:549-560
7. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241
8. France CP, Woods JH (1989) Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250:937-943
9. France CP, de Costa BR, Jacobson AE, Rice KC, Woods JH (1990) Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. J Pharmacol Exp Ther 252:600-604
10. Gerak LR, France CP (2007) Time-dependent decreases in apparent pA2 values for naltrexone studied in combination with morphine in rhesus monkeys. Psychopharmacology 193:315-321
11. Gonzalez G, Oliverto A, Kosten TR (2004) Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 5:713-725
12. Hamad MO, Kiptoo PK, Stinchbomb AL, Crooks PA (2006) Synthesis and hydrolytic behavior of two novel tripartite codrugs of naltrexone and 6β-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorg Med Chem 14:7051-7061
13. 2 receptor antagonists on a cranial nerve reflex in the rabbit: evidence for inverse agonism. Psychopharmacology 141:162-168
14. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL (2006) Enhancement of transdermal delivery of 6β-naltrexol via a codrug linked to hydroxybupropion. J Control Release 113:137-145
15. Ko MC, Divin MF, Lee H, Woods JH, Traynor JR (2006) Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey. J Pharmacol Exp Ther 316:772-779
16. Malspeis L, Bathala MS, Ludden TM, Bhat HB, Frank SG, Sokoloski TD, Morrison BE, Reuning RH (1975) Metabolic reduction of naltrexone. I. Synthesis, separation and characterization of naloxone and naltrexone reduction products and qualitative assay of urine and bile following administration of naltrexone, alpha-naltrexol, or beta-naltrexol. Res Commun Chem Pathol Pharmacol 12:43-65
17. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45:15-19
18. Milligan G, Bond RA, Lee M (1995) Inverse agonism, pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol Sci 16:10-13
19. 3H)naltrexone in the central nervous system of the rat. Drug Metab Dispos 4:276-280
20. Porter SJ, Somogyi AA, White JM (2002) In vivo and in vitro studies of 6β-naltrexol, the major human metabolite of naltrexone. Addict Biol 7:218-225
21. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadee W, Bilsky EJ (2005) In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 313:1150-1162
22. 2A receptor in vivo. Psychopharmacology 184:173-181
23. 2-adrenergic receptor: extending the ternary complex model. J Biol Chem 268:4625-4636
24. Tallarida RJ, Cowan A, Adler MW (1979) pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci 25:637-654
25. Walker EA, Sterious SN (2005) Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence. Br J Pharmacol 145:975-983
26. Wang D, Raehal KM, Bilsky EJ, Sadee W (2001) Inverse agonists and neutral antagonists at. μ. opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600
27. Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, Sadee W (2004) Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308:512-520
28. Wang D, Sun X, Sadee W (2007) Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321:544-552
29. Wang Z, Edward JB, Porreca F, Sadee W (1994) Constitutive μ-opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54:PL339-PL350